| 2933.19.30 | 10 | Couplers, for use in color negative photographic paper | kg | | | |
| 2933.19.30 | 15 | Coupler dispersions, for use in color negative photographic paper | kg | | | |
| 2933.21.00 | 00 | Compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.31.00 | 00 | Compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.41.00 | 00 | Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2933.59.21 | 00 | Antihistamines, including those principally used as anti-nauseants | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¢/kg + 82% |
| 2933.61.00 | 00 | Compounds containing an unfused triazine ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.69.60 | 30 | Products used principally for rubber processing | kg | | | |
| 2933.99.55 | 30 | Tolmetin sodium (anhydrous) | kg | | | |
| 2933.99.55 | | Drugs primarily affecting the central nervous system: | | | | |
| 2934.10 | | Compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure: | | | | |
| 2934.20 | | Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.30 | | Compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2936 | | Provitamins and vitamins, natural or reproduced by synthesis (including natural concentrates), derivatives thereof used primarily as vitamins, and intermixtures of the foregoing, whether or not in any solvent: | | | | |
| 2937 | | Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis; derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones: | | | | |
| 3001 | | Glands and other organs for organotherapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organotherapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included: | | | | |
| 3002 | | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: | | | | |
| 3003 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale: | | | | |
| 3004 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: | | | | |
| 3004.10.10 | 10 | For veterinary use | kg | | | |
| 3004.10.50 | 10 | For veterinary use | kg | | | |
| 3004.20.00 | 10 | For veterinary use | kg | | | |
| 3004.39.00 | 10 | For veterinary use | kg | | | |
| 3004.40.00 | 05 | For veterinary use | kg | | | |
| 3004.40.00 | 20 | Medicaments primarily affecting the central nervous system: | | | | |
Harmonized Tariff Schedule of the United States inquiry: 3203Ã
